



Clinical trial results:

A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ejection Fraction > 40%

Summary

EudraCT number	2020-005844-47
Trial protocol	SE SK CZ DK BG FR HU PL NL BE
Global end of trial date	27 March 2024

Results information

Result version number	v1 (current)
This version publication date	11 April 2025
First version publication date	11 April 2025

Trial information

Trial identification

Sponsor protocol code	D6580C00010
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04986202
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	151 85, Södertälje, Sweden,
Public contact	Global Clinical Lead, AstraZeneca, +1 8772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, +1 8772409479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 June 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	27 March 2024
Global end of trial reached?	Yes
Global end of trial date	27 March 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy and safety of mitiperstat (previously known as AZD4831) in participants with heart failure (HF) with left ventricular ejection fraction (LVEF) > 40%.

Protection of trial subjects:

Patients given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 June 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 9
Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Brazil: 42
Country: Number of subjects enrolled	Bulgaria: 96
Country: Number of subjects enrolled	Canada: 22
Country: Number of subjects enrolled	Czechia: 67
Country: Number of subjects enrolled	Denmark: 25
Country: Number of subjects enrolled	France: 19
Country: Number of subjects enrolled	Hungary: 56
Country: Number of subjects enrolled	Japan: 75
Country: Number of subjects enrolled	Netherlands: 14
Country: Number of subjects enrolled	Poland: 69
Country: Number of subjects enrolled	Russian Federation: 15
Country: Number of subjects enrolled	Slovakia: 76
Country: Number of subjects enrolled	Sweden: 37
Country: Number of subjects enrolled	Taiwan: 30
Country: Number of subjects enrolled	Türkiye: 4
Country: Number of subjects enrolled	United States: 50
Worldwide total number of subjects	709
EEA total number of subjects	468

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	106
From 65 to 84 years	595
85 years and over	8

Subject disposition

Recruitment

Recruitment details:

A total of 142 study centres in 18 countries randomised participants.

Pre-assignment

Screening details:

The discrepancy between the number of randomised participants and the number of participants in the full analysis set and the safety analysis set is because only randomized participants who have taken at least one dose of the investigational product (IP) were included in the analysis sets.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Carer, Data analyst, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	AZD4831 2.5 mg

Arm description:

Once-daily oral dosing of AZD4831 2.5 mg

Arm type	Experimental
Investigational medicinal product name	AZD4831
Investigational medicinal product code	
Other name	Mitiperstat
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2.5 mg once daily

Arm title	AZD4831 5 mg
------------------	--------------

Arm description:

Once-daily oral dosing of AZD4831 5 mg

Arm type	Experimental
Investigational medicinal product name	AZD4831
Investigational medicinal product code	
Other name	Mitiperstat
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

5 mg once daily

Arm title	Placebo
------------------	---------

Arm description:

Once-daily oral dosing of placebo

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Once daily

Number of subjects in period 1	AZD4831 2.5 mg	AZD4831 5 mg	Placebo
Started	234	240	235
Completed	218	234	220
Not completed	16	6	15
Adverse event, serious fatal	10	3	10
Physician decision	2	1	2
Consent withdrawn by subject	4	2	3

Baseline characteristics

Reporting groups

Reporting group title	AZD4831 2.5 mg
Reporting group description:	
Once-daily oral dosing of AZD4831 2.5 mg	
Reporting group title	AZD4831 5 mg
Reporting group description:	
Once-daily oral dosing of AZD4831 5 mg	
Reporting group title	Placebo
Reporting group description:	
Once-daily oral dosing of placebo	

Reporting group values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo
Number of subjects	234	240	235
Age Categorical			
Units: Participants			
< 65 Years	34	42	30
65 - 75 Years	120	108	115
> 75 Years	80	90	90
Age Continuous			
Units: Years			
arithmetic mean	72.5	72.1	72.5
standard deviation	± 7.3	± 7.1	± 7.8
Sex: Female, Male			
Units: Participants			
Female	107	119	96
Male	127	121	139
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	16	14	21
Not Hispanic or Latino	218	226	214
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	35	36	36
Black or African American	5	10	6
Native Hawaiian or Other Pacific Islander	0	0	0
White	193	194	192
Other	1	0	1
Not Reported	0	0	0
Region of Enrollment			
Units: Subjects			
Australia	1	1	1
Belgium	3	3	3
Brazil	13	14	15
Bulgaria	33	32	31
Canada	8	8	6

Czech Republic	23	22	22
Denmark	8	9	8
France	6	7	6
Hungary	18	19	19
Japan	25	25	25
Netherlands	4	5	5
Poland	22	23	24
Russian Federation	5	5	5
Slovakia	25	26	25
Sweden	12	12	13
Taiwan	10	10	10
Turkey	1	2	1
United States of America	17	17	16

Reporting group values	Total		
Number of subjects	709		
Age Categorical			
Units: Participants			
< 65 Years	106		
65 - 75 Years	343		
> 75 Years	260		
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Participants			
Female	322		
Male	387		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	51		
Not Hispanic or Latino	658		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	107		
Black or African American	21		
Native Hawaiian or Other Pacific Islander	0		
White	579		
Other	2		
Not Reported	0		
Region of Enrollment			
Units: Subjects			
Australia	3		
Belgium	9		
Brazil	42		
Bulgaria	96		
Canada	22		
Czech Republic	67		
Denmark	25		

France	19		
Hungary	56		
Japan	75		
Netherlands	14		
Poland	69		
Russian Federation	15		
Slovakia	76		
Sweden	37		
Taiwan	30		
Turkey	4		
United States of America	50		

End points

End points reporting groups

Reporting group title	AZD4831 2.5 mg
Reporting group description:	
Once-daily oral dosing of AZD4831 2.5 mg	
Reporting group title	AZD4831 5 mg
Reporting group description:	
Once-daily oral dosing of AZD4831 5 mg	
Reporting group title	Placebo
Reporting group description:	
Once-daily oral dosing of placebo	

Primary: Kansas City Cardiomyopathy Questionnaire -Total Symptom Score 16 weeks

End point title	Kansas City Cardiomyopathy Questionnaire -Total Symptom Score 16 weeks
End point description:	
Kansas City Cardiomyopathy Questionnaire -Total Symptom Score change from baseline at 16 weeks compared with placebo Part A. The score ranges from 0 to 100, where a higher score represents a better patient outcome	
End point type	Primary
End point timeframe:	
Baseline - 16 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	211	221	220	
Units: Points				
least squares mean (confidence interval 95%)	10.70 (8.58 to 12.82)	9.81 (7.73 to 11.90)	11.62 (9.54 to 13.71)	

Statistical analyses

Statistical analysis title	Difference in least-squares means
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.221 ^[1]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.81

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.71
upper limit	1.09

Notes:

[1] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	431
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.537 [2]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.86
upper limit	2.02

Notes:

[2] - Two-sided test.

Primary: Six Minute Walk Distance 16 weeks

End point title	Six Minute Walk Distance 16 weeks
End point description: Six Minute Walk Distance change from baseline at 16 weeks compared with placebo Part A	
End point type	Primary
End point timeframe: Baseline - 16 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	210	223	223	
Units: Meters				
least squares mean (confidence interval 95%)	15.3 (9.4 to 21.2)	18.2 (12.4 to 23.9)	12.9 (7.2 to 18.7)	

Statistical analyses

Statistical analysis title	Difference in least-squares means
Comparison groups	AZD4831 5 mg v Placebo

Number of subjects included in analysis	446
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.195 ^[3]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	13.3

Notes:

[3] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	433
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.559 ^[4]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.7
upper limit	10.5

Notes:

[4] - Two-sided test.

Secondary: Kansas City Cardiomyopathy Questionnaire-Total Symptom Score

End point title	Kansas City Cardiomyopathy Questionnaire-Total Symptom Score
-----------------	--

End point description:

Kansas City Cardiomyopathy Questionnaire -Total Symptom Score change from baseline at 24 and 48 weeks compared with placebo Part A. The score ranges from 0 to 100, where a higher score represents a better patient outcome.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - 24 and 48 weeks

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	208 ^[5]	225 ^[6]	210 ^[7]	
Units: Points				
least squares mean (confidence interval 95%)				
Change from baseline at 24 weeks	11.13 (8.94 to 13.32)	11.92 (9.80 to 14.03)	12.78 (10.59 to 14.97)	
Change from baseline at 48 weeks	12.78 (10.25 to 15.30)	11.98 (9.50 to 14.46)	13.03 (10.47 to 15.58)	

Notes:

[5] - For 48 weeks, the number of subjects analyzed is 194.

[6] - For 48 weeks, the number of subjects analyzed is 204.

[7] - For 48 weeks, the number of subjects analyzed is 193.

Statistical analyses

Statistical analysis title	Difference in least-squares means
Statistical analysis description:	
Change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	418
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.289 ^[8]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.71
upper limit	1.41

Notes:

[8] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description:	
Change from baseline at 48 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	435
Analysis specification	Pre-specified
Analysis type	superiority ^[9]
P-value	= 0.558 ^[10]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.55
upper limit	2.46

Notes:

[9] - For 48 weeks, the number of subjects in the analysis is 397

[10] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 48 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	418
Analysis specification	Pre-specified
Analysis type	superiority ^[11]
P-value	= 0.89 ^[12]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.3

Notes:

[11] - For 48 weeks, the number of subjects in the analysis is 387.

[12] - Two-sided test.

Statistical analysis title	Difference in least-squares mean
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	435
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.571 ^[13]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.86
upper limit	2.13

Notes:

[13] - Two-sided test.

Secondary: Six Minute Walk Distance

End point title	Six Minute Walk Distance
End point description: Six Minute Walk Distance change from baseline at 24 and 48 weeks compared with placebo Part A	
End point type	Secondary
End point timeframe: Baseline - 24 and 48 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	202 ^[14]	222 ^[15]	211 ^[16]	
Units: Meters				
least squares mean (confidence interval 95%)				
Change from baseline at 24 weeks	13.5 (7.1 to 19.8)	18.5 (12.4 to 24.6)	15.7 (9.4 to 22.0)	
Change from baseline at 48 weeks	19.2 (11.9 to 26.4)	15.7 (8.6 to 22.7)	13.5 (6.3 to 20.6)	

Notes:

[14] - For 48 weeks, the number of subjects analyzed is 190.

[15] - For 48 weeks, the number of subjects analyzed is 205.

[16] - For 48 weeks, the number of subjects analyzed is 201.

Statistical analyses

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.619 ^[17]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.1
upper limit	6.6

Notes:

[17] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 48 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority ^[18]
P-value	= 0.267 ^[19]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	5.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	15.8

Notes:

[18] - For 48 weeks, the number of subjects in the analysis is 391

[19] - Two-sided test.

Statistical analysis title	Difference in least-squares means
-----------------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 48 weeks

Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	433
Analysis specification	Pre-specified
Analysis type	superiority ^[20]
P-value	= 0.657 ^[21]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	2.2

Confidence interval

level	95 %
sides	2-sided
lower limit	-7.6
upper limit	12.1

Notes:

[20] - For 48 weeks, the number of subjects in the analysis is 406

[21] - Two-sided test.

Statistical analysis title	Difference in least-squares means
-----------------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 24 weeks

Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	433
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.522 ^[22]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	2.8

Confidence interval

level	95 %
sides	2-sided
lower limit	-5.8
upper limit	11.4

Notes:

[22] - Two-sided test.

Secondary: N-terminal pro-brain natriuretic peptide (NT-proBNP)

End point title	N-terminal pro-brain natriuretic peptide (NT-proBNP)
-----------------	--

End point description:

NT-proBNP change from baseline at 16, 24, and 48 weeks compared with placebo Part A

End point type Secondary

End point timeframe:

Baseline - 16, 24 and 48 weeks

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	212 ^[23]	223 ^[24]	220 ^[25]	
Units: ng/L				
geometric mean (confidence interval 95%)				
NT-proBNP change from baseline at 16 weeks	1.00 (0.93 to 1.08)	0.96 (0.90 to 1.03)	1.05 (0.98 to 1.13)	
NT-proBNP change from baseline at 24 weeks	1.00 (0.92 to 1.07)	1.00 (0.93 to 1.08)	0.99 (0.92 to 1.07)	
NT-proBNP change from baseline at 48 weeks	1.02 (0.94 to 1.11)	1.00 (0.93 to 1.09)	1.08 (0.99 to 1.17)	

Notes:

[23] - For 24 and 48 weeks, the numbers of subjects analyzed are 210 and 195.

[24] - For 24 and 48 weeks, the numbers of subjects analyzed are 228 and 212.

[25] - For 24 and 48 weeks, the numbers of subjects analyzed are 218 and 201.

Statistical analyses

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description:	
NT-proBNP change from baseline at 16 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.312 ^[26]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	1.05

Notes:

[26] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description:	
NT-proBNP change from baseline at 16 weeks	
Comparison groups	AZD4831 5 mg v Placebo

Number of subjects included in analysis	443
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.07 [27]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.01

Notes:

[27] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: NT-proBNP change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority ^[28]
P-value	= 0.911 [29]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.91
upper limit	1.12

Notes:

[28] - For 24 weeks, the number of subjects in the analysis is 428

[29] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: NT-proBNP change from baseline at 24 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	443
Analysis specification	Pre-specified
Analysis type	superiority ^[30]
P-value	= 0.837 [31]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.91
upper limit	1.12

Notes:

[30] - For 24 weeks, the number of subjects in the analysis is 446

[31] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: NT-proBNP change from baseline at 48 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority ^[32]
P-value	= 0.37 ^[33]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.07

Notes:

[32] - For 48 weeks, the number of subjects in the analysis is 396

[33] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: NT-proBNP change from baseline at 48 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	443
Analysis specification	Pre-specified
Analysis type	superiority ^[34]
P-value	= 0.205 ^[35]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.04

Notes:

[34] - For 48 weeks, the number of subjects in the analysis is 413

[35] - Two-sided test.

Secondary: Left ventricular global longitudinal strain (LV-GLS)

End point title	Left ventricular global longitudinal strain (LV-GLS)
End point description: LV-GLS change from baseline at 16 and 24 weeks compared with placebo Part A	
End point type	Secondary
End point timeframe: Baseline - 16 and 24 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	109 ^[36]	121 ^[37]	117 ^[38]	
Units: Percentage (%)				
least squares mean (confidence interval 95%)				
LV-GLS change from baseline at 16 weeks	0.1 (-0.5 to 0.6)	-0.5 (-1.0 to 0.0)	-0.4 (-1.0 to 0.1)	
LV-GLS change from baseline at 24 weeks	-0.6 (-1.1 to 0.0)	-0.9 (-1.4 to -0.4)	-1.0 (-1.5 to -0.4)	

Notes:

[36] - For 24 weeks, the number of subjects analyzed is 114.

[37] - For 24 weeks, the number of subjects analyzed is 132.

[38] - For 24 weeks, the number of subjects analyzed is 121.

Statistical analyses

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 16 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.183 ^[39]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	1.2

Notes:

[39] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	226
Analysis specification	Pre-specified
Analysis type	superiority ^[40]
P-value	= 0.316 ^[41]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	1.1

Notes:

[40] - For 24 weeks, the number of subjects in the analysis is 235

[41] - Two-sided test.

Statistical analysis title	Difference in least-squares means
-----------------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 24 weeks

Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	238
Analysis specification	Pre-specified
Analysis type	superiority ^[42]
P-value	= 0.934 ^[43]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.8

Notes:

[42] - For 24 weeks, the number of subjects in the analysis is 253

[43] - Two-sided test.

Statistical analysis title	Difference in least-squares means
-----------------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 16 weeks

Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	238
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.898 ^[44]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.7

Notes:

[44] - Two-sided test.

Secondary: Left atrial volume index (LAVI)

End point title	Left atrial volume index (LAVI)
-----------------	---------------------------------

End point description:

LAVI change from baseline at 16 and 24 weeks compared with placebo Part A

End point type Secondary

End point timeframe:

Baseline - 16 and 24 weeks

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	184 ^[45]	196 ^[46]	184 ^[47]	
Units: mL/m2				
least squares mean (confidence interval 95%)				
LAVI change from baseline at 16 weeks	-0.940 (-2.373 to 0.493)	-1.894 (-3.286 to -0.502)	-1.300 (-2.743 to 0.144)	
LAVI change from baseline at 24 weeks	1.096 (-0.626 to 2.818)	-0.376 (-1.986 to 1.235)	0.439 (-1.236 to 2.114)	

Notes:

[45] - For 24 weeks, the number of subjects analyzed is 176.

[46] - For 24 weeks, the number of subjects analyzed is 201.

[47] - For 24 weeks, the number of subjects analyzed is 189.

Statistical analyses

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 16 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	368
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.725 ^[48]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.647
upper limit	2.366

Notes:

[48] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 16 weeks	
Comparison groups	AZD4831 5 mg v Placebo

Number of subjects included in analysis	380
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.555 ^[49]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.594
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.571
upper limit	1.382

Notes:

[49] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	368
Analysis specification	Pre-specified
Analysis type	superiority ^[50]
P-value	= 0.586 ^[51]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.657
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.71
upper limit	3.025

Notes:

[50] - For 24 weeks, the number of subjects in the analysis is 365

[51] - Two-sided test.

Statistical analysis title	Difference in least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	380
Analysis specification	Pre-specified
Analysis type	superiority ^[52]
P-value	= 0.486 ^[53]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.815
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.108
upper limit	1.478

Notes:

[52] - For 24 weeks, the number of subjects in the analysis is 390

[53] - Two-sided test.

Secondary: Left ventricular mass index (LVMI)

End point title	Left ventricular mass index (LVMI)
-----------------	------------------------------------

End point description:

LVMI change from baseline at 16 and 24 weeks compared with placebo Part A

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - 16 and 24 weeks

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200 ^[54]	208 ^[55]	204 ^[56]	
Units: g/m ²				
least squares mean (confidence interval 95%)				
LVMI change from baseline at 16 weeks	1.3 (-1.6 to 4.2)	-0.9 (-3.8 to 1.9)	1.4 (-1.5 to 4.2)	
LVMI change from baseline at 24 weeks	9.8 (6.0 to 13.5)	8.3 (4.6 to 11.9)	9.4 (5.6 to 13.1)	

Notes:

[54] - For 24 weeks, the number of subjects analyzed is 197.

[55] - For 24 weeks, the number of subjects analyzed is 213.

[56] - For 24 weeks, the number of subjects analyzed is 202.

Statistical analyses

Statistical analysis title	Difference in least-squares means
----------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 16 weeks

Comparison groups	AZD4831 2.5 mg v Placebo
-------------------	--------------------------

Number of subjects included in analysis	404
---	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	superiority
---------------	-------------

P-value	= 0.968 ^[57]
---------	-------------------------

Method	ANCOVA
--------	--------

Parameter estimate	Mean difference (final values)
--------------------	--------------------------------

Point estimate	-0.1
----------------	------

Confidence interval

level	95 %
-------	------

sides	2-sided
-------	---------

lower limit	-4.1
-------------	------

upper limit	3.9
-------------	-----

Notes:

[57] - Two-sided test.

Statistical analysis title	Difference in least-squares means
----------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 16 weeks

Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	412
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.251 ^[58]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.3
upper limit	1.6

Notes:

[58] - Two-sided test.

Statistical analysis title	Difference in least-squares means
-----------------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 24 weeks

Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority ^[59]
P-value	= 0.872 ^[60]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	5.7

Notes:

[59] - For 24 weeks, the number of subjects in the analysis is 399

[60] - Two-sided test.

Statistical analysis title	Difference in least-squares means
-----------------------------------	-----------------------------------

Statistical analysis description:

Change from baseline at 24 weeks

Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	412
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.682 ^[61]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	4.1

Notes:

[61] - Two-sided test.

Secondary: Pharmacokinetics (AZD4831 plasma exposure)

End point title	Pharmacokinetics (AZD4831 plasma exposure)
End point description: Plasma concentrations of AZD4831 summarised by timepoint and dose level Part A	
End point type	Secondary
End point timeframe: Baseline, 4 weeks, 12 weeks, 16 weeks, 24 weeks, 48 weeks, 52 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	231 ^[62]	238 ^[63]	0 ^[64]	
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Baseline (pre-dose)	1.02 (± 19.57)	1.01 (± 9.38)	()	
4 weeks (pre-dose)	14.45 (± 99.26)	26.44 (± 141.88)	()	
12 weeks (pre-dose)	13.51 (± 130.33)	25.45 (± 161.09)	()	
16 weeks (pre-dose)	13.59 (± 126.71)	25.31 (± 159.79)	()	
24 weeks (pre-dose)	12.87 (± 146.45)	23.08 (± 199.18)	()	
48 weeks (pre-dose)	10.36 (± 188.55)	21.18 (± 229.28)	()	
52 weeks (pre-dose)	1.14 (± 49.22)	1.27 (± 74.56)	()	

Notes:

[62] - The number of subjects analyzed is for baseline and varies for other timepoints.

[63] - The number of subjects analyzed is for baseline and varies for other timepoints.

[64] - No samples from participants on placebo were analysed.

Statistical analyses

No statistical analyses for this end point

Secondary: High sensitivity CRP (hsCRP)

End point title	High sensitivity CRP (hsCRP)
End point description: hsCRP change from baseline at 16, 24, and 48 weeks compared with placebo Part A	
End point type	Secondary
End point timeframe: Baseline - 16, 24 and 48 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	210 ^[65]	224 ^[66]	218 ^[67]	
Units: mg/dL				
geometric mean (confidence interval 95%)				
hsCRP change from baseline at 16 weeks	0.940 (0.824 to 1.073)	1.105 (0.971 to 1.257)	0.914 (0.802 to 1.041)	
hsCRP change from baseline at 24 weeks	1.029 (0.907 to 1.168)	1.101 (0.976 to 1.243)	0.926 (0.816 to 1.051)	
hsCRP change from baseline at 48 weeks	1.120 (0.973 to 1.288)	1.127 (0.985 to 1.290)	0.972 (0.845 to 1.119)	

Notes:

[65] - For 24 and 48 weeks, the numbers of subjects analyzed are 209 and 196.

[66] - For 24 and 48 weeks, the numbers of subjects analyzed are 229 and 215.

[67] - For 24 and 48 weeks, the numbers of subjects analyzed are 210 and 197.

Statistical analyses

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 16 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	428
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.76 ^[68]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.029
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.857
upper limit	1.236

Notes:

[68] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 48 weeks	
Comparison groups	AZD4831 5 mg v Placebo

Number of subjects included in analysis	442
Analysis specification	Pre-specified
Analysis type	superiority ^[69]
P-value	= 0.131 ^[70]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.159
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.957
upper limit	1.404

Notes:

[69] - For 48 weeks, the number of subjects in the analysis is 412

[70] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description:	
Change from baseline at 24 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	442
Analysis specification	Pre-specified
Analysis type	superiority ^[71]
P-value	= 0.049 ^[72]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.001
upper limit	1.414

Notes:

[71] - For 24 weeks, the number of subjects in the analysis is 439

[72] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description:	
Change from baseline at 48 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	428
Analysis specification	Pre-specified
Analysis type	superiority ^[73]
P-value	= 0.158 ^[74]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.151
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.946
upper limit	1.401

Notes:

[73] - For 48 weeks, the number of subjects in the analysis is 393

[74] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 16 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	442
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.039 [75]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.209
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.01
upper limit	1.448

Notes:

[75] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	428
Analysis specification	Pre-specified
Analysis type	superiority ^[76]
P-value	= 0.241 [77]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.111
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.931
upper limit	1.326

Notes:

[76] - For 24 weeks, the number of subjects in the analysis is 419

[77] - Two-sided test.

Secondary: Interleukin 6 (IL-6)

End point title	Interleukin 6 (IL-6)
End point description: IL-6 change from baseline at 16, 24, and 48 weeks compared with placebo Part A	
End point type	Secondary
End point timeframe: Baseline - 16, 24 and 48 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	190 ^[78]	201 ^[79]	199 ^[80]	
Units: ng/L				
geometric mean (confidence interval 95%)				
IL-6 change from baseline at 16 weeks	1.1326 (1.0261 to 1.2502)	1.0258 (0.9316 to 1.1295)	1.1202 (1.0170 to 1.2339)	
IL-6 change from baseline at 24 weeks	1.0918 (0.9934 to 1.2000)	1.0700 (0.9777 to 1.1711)	0.9869 (0.8975 to 1.0852)	
IL-6 change from baseline at 48 weeks	1.3328 (1.2134 to 1.4639)	1.3094 (1.1972 to 1.4321)	1.2698 (1.1574 to 1.3931)	

Notes:

[78] - For 24 and 48 weeks, the numbers of subjects analyzed are 189 and 170.

[79] - For 24 and 48 weeks, the numbers of subjects analyzed are 209 and 189.

[80] - For 24 and 48 weeks, the numbers of subjects analyzed are 188 and 177.

Statistical analyses

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description:	
Change from baseline at 16 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	389
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.874 ^[81]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.0111
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8819
upper limit	1.1592

Notes:

[81] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description:	
Change from baseline at 16 weeks	
Comparison groups	AZD4831 5 mg v Placebo

Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2 ^[82]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.9157
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8002
upper limit	1.0479

Notes:

[82] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 48 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.636 ^[83]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.0312
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.908
upper limit	1.1711

Notes:

[83] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 5 mg v Placebo
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority ^[84]
P-value	= 0.22 ^[85]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.0842
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9527
upper limit	1.2339

Notes:

[84] - For 24 weeks, the number of subjects in the analysis is 397

[85] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 48 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	389
Analysis specification	Pre-specified
Analysis type	superiority ^[86]
P-value	= 0.467 ^[87]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.0496
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9211
upper limit	1.196

Notes:

[86] - For 48 weeks, the number of subjects in the analysis is 347

[87] - Two-sided test.

Statistical analysis title	Difference in geometric least-squares means
Statistical analysis description: Change from baseline at 24 weeks	
Comparison groups	AZD4831 2.5 mg v Placebo
Number of subjects included in analysis	389
Analysis specification	Pre-specified
Analysis type	superiority ^[88]
P-value	= 0.135 ^[89]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.1063
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.969
upper limit	1.2631

Notes:

[88] - For 24 weeks, the number of subjects in the analysis is 377

[89] - Two-sided test.

Other pre-specified: Adverse Events

End point title	Adverse Events
End point description: Number of participants with Adverse Events Part A	
End point type	Other pre-specified
End point timeframe: Baseline - 52 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	234	240	235	
Units: Participants	173	180	173	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Vital Signs

End point title	Vital Signs
End point description:	
Number of participants with treatment emergent vital sign abnormalities Part A	
End point type	Other pre-specified
End point timeframe:	
Baseline - 52 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	233 ^[90]	240 ^[91]	235 ^[92]	
Units: Participants				
DBP \geq 90 & increase fr baseline \geq 10 (mmHg)	62	60	68	
DBP $<$ 60 & decrease fr baseline \geq 10 (mmHg)	32	42	33	
Pulse \geq 100 & increase fr baseline \geq 20 (beats/min)	15	17	11	
Pulse $<$ 50 & decrease fr baseline \geq 20 (beats/min)	2	6	8	
SBP \geq 140 & increase fr baseline \geq 20 (mmHg)	71	84	67	
SBP $<$ 90 & decrease fr baseline \geq 20 (mmHg)	5	3	3	

Notes:

[90] - Number of subjects with a baseline value and at least one post-baseline value.

[91] - Number of subjects with a baseline value and at least one post-baseline value.

[92] - Number of subjects with a baseline value and at least one post-baseline value.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Clinical Laboratory

End point title	Clinical Laboratory
End point description:	
Number of participants with outliers for clinical laboratory measurements Part A	
End point type	Other pre-specified
End point timeframe:	
Baseline - 52 weeks	

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	227 ^[93]	238 ^[94]	232 ^[95]	
Units: Participants				
Eosinophils ≥ 0.7 ($10^9/L$)	4	4	8	
Eosinophils ≥ 1.5 ($10^9/L$)	0	0	0	
Hemoglobin < 100 ($10^9/L$)	9	11	6	
Hemoglobin < 8 ($10^9/L$)	1	1	0	
Neutrophil count < 1.5 ($10^9/L$)	2	7	3	
Neutrophil count < 1.0 ($10^9/L$)	0	1	0	
Leukocytes < 3.0 ($10^9/L$)	3	5	6	
Leukocytes < 2.0 ($10^9/L$)	0	1	0	
ALP $> 1.5x$ ULN	9	8	13	
ALP $> 3x$ ULN	0	0	1	
ALT $> 3x$ ULN	5	2	3	
ALT $> 5x$ ULN	2	0	1	
ALT $> 10x$ ULN	0	0	0	
AST $> 3x$ ULN	3	3	4	
AST $> 5x$ ULN	1	0	0	
AST $> 10x$ ULN	0	0	0	
Creatinine $\geq 1.5x$ baseline creatinine	15	10	14	
Creatinine $\geq 2x$ baseline creatinine	3	0	2	
TB $> 1.5x$ ULN	6	1	12	
TB $> 2x$ ULN	1	1	2	
AST or ALT $> 3x$ ULN	6	3	4	
AST or ALT $> 3x$ ULN and TB $> 2x$ ULN	0	0	1	
TSH ≥ 6 (mIU/L)	19	25	18	
TSH ≥ 10 (mIU/L)	12	6	3	
TSH > 6 and free T4 $< LLN$ (mIU/L)	2	1	0	
TSH ≥ 10 and free T4 $< LLN$ (mIU/L)	2	0	0	

Notes:

[93] - Number of subjects with a baseline value and at least one post-baseline value.

[94] - Number of subjects with a baseline value and at least one post-baseline value. Chemistry: 239

[95] - Number of subjects with a baseline value and at least one post-baseline value.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Electrocardiogram (ECG)

End point title	Electrocardiogram (ECG)
-----------------	-------------------------

End point description:

Number of Participants With Abnormal ECG Last On-Study Value Part A

End point type Other pre-specified

End point timeframe:

Baseline - 52 weeks

End point values	AZD4831 2.5 mg	AZD4831 5 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	226 ^[96]	239 ^[97]	232 ^[98]	
Units: Participants				
Normal; Normal at baseline	43	52	49	
Abn, not clin sig; Normal at baseline	17	19	14	
Abn, clin sig last on-study; Normal at baseline	2	0	1	
Normal; Abn, not clin sig at baseline	8	14	7	
Abn, not clin sig; Abn, not clin sig at baseline	132	135	137	
Abn, clin sig; Abn, not clin sig at baseline	5	2	4	
Normal; Abn, clin sig at baseline	0	0	1	
Abn, not clin sig; Abn clin sig at baseline	6	7	12	
Abn, clin sig; Abn, clin sig at baseline	13	10	7	

Notes:

[96] - Number of subjects with a baseline value and at least one post-baseline value.

[97] - Number of subjects with a baseline value and at least one post-baseline value.

[98] - Number of subjects with a baseline value and at least one post-baseline value.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until last study visit

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	AZD4831 2.5mg
-----------------------	---------------

Reporting group description: -

Reporting group title	AZD4831 5mg
-----------------------	-------------

Reporting group description: -

Serious adverse events	Placebo	AZD4831 2.5mg	AZD4831 5mg
Total subjects affected by serious adverse events			
subjects affected / exposed	56 / 235 (23.83%)	60 / 234 (25.64%)	57 / 240 (23.75%)
number of deaths (all causes)	10	10	3
number of deaths resulting from adverse events	10	10	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Carcinoid tumour pulmonary			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal adenoma			

subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip squamous cell carcinoma			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma metastatic			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland neoplasm			

subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Brachiocephalic arteriosclerosis			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 235 (0.43%)	1 / 234 (0.43%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iliac artery embolism			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular insufficiency			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sudden death			

subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Social circumstances			
Alcohol use			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Respiratory failure			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	2 / 235 (0.85%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	2 / 240 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Dyspnoea			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 235 (0.43%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood sodium decreased			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-reactive protein increased			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chemical burn			

subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 235 (0.00%)	2 / 234 (0.85%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Scapula fracture			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			

subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			

subjects affected / exposed	1 / 235 (0.43%)	4 / 234 (1.71%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	2 / 235 (0.85%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			
subjects affected / exposed	3 / 235 (1.28%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	2 / 235 (0.85%)	3 / 234 (1.28%)	3 / 240 (1.25%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	3 / 235 (1.28%)	2 / 234 (0.85%)	5 / 240 (2.08%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	2 / 235 (0.85%)	1 / 234 (0.43%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial tachycardia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			

subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	13 / 235 (5.53%)	10 / 234 (4.27%)	13 / 240 (5.42%)
occurrences causally related to treatment / all	0 / 15	0 / 11	0 / 16
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cardiac arrest			
subjects affected / exposed	2 / 235 (0.85%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Ventricular tachycardia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			
subjects affected / exposed	2 / 235 (0.85%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis constrictive			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve stenosis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			

subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 235 (0.00%)	2 / 234 (0.85%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cerebral infarction			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	1 / 235 (0.43%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic neuritis			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 235 (0.43%)	3 / 234 (1.28%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Epilepsy			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia			

subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	2 / 240 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Blood and lymphatic system disorders			
Immune thrombocytopenia			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normocytic anaemia			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vestibular disorder			
subjects affected / exposed	1 / 235 (0.43%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blindness			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cataract			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vision blurred			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scleritis			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Duodenal ulcer perforation			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			

subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 235 (0.00%)	2 / 234 (0.85%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumoperitoneum			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			

subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erythema multiforme			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	2 / 240 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Acute kidney injury			

subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	2 / 240 (0.83%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 235 (0.00%)	2 / 234 (0.85%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

COVID-19			
subjects affected / exposed	0 / 235 (0.00%)	3 / 234 (1.28%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 235 (0.43%)	2 / 234 (0.85%)	2 / 240 (0.83%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cellulitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis orbital			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Citrobacter bacteraemia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 235 (0.85%)	2 / 234 (0.85%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			

subjects affected / exposed	0 / 235 (0.00%)	2 / 234 (0.85%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella urinary tract infection			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	2 / 235 (0.85%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periodontitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 235 (0.43%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia moraxella			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			

subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sepsis			
subjects affected / exposed	3 / 235 (1.28%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Septic shock			
subjects affected / exposed	1 / 235 (0.43%)	1 / 234 (0.43%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 235 (0.00%)	2 / 234 (0.85%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection bacterial			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			

subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 234 (0.00%)	1 / 240 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour lysis syndrome			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 235 (0.43%)	0 / 234 (0.00%)	0 / 240 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	AZD4831 2.5mg	AZD4831 5mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	45 / 235 (19.15%)	49 / 234 (20.94%)	44 / 240 (18.33%)
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	14 / 235 (5.96%)	11 / 234 (4.70%)	11 / 240 (4.58%)
occurrences (all)	14	14	13
Nervous system disorders			

Dizziness subjects affected / exposed occurrences (all)	12 / 235 (5.11%) 15	18 / 234 (7.69%) 21	10 / 240 (4.17%) 12
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	15 / 235 (6.38%) 21	9 / 234 (3.85%) 12	13 / 240 (5.42%) 15
COVID-19 subjects affected / exposed occurrences (all)	15 / 235 (6.38%) 15	16 / 234 (6.84%) 16	18 / 240 (7.50%) 18

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 May 2021	Amendment 1
01 November 2021	Amendment 2
09 February 2022	Amendment 3
23 September 2022	Amendment 4

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported